Farallon Capital Management
Farallon Capital Management, L.L.C. is an American multi-strategy hedge fund and global institutional investment firm founded in 1986. It invests in public and private assets worldwide through bottom-up fundamental research across value investments, credit investments, merger arbitrage, real estate, and direct investments.
48% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Average disclosed round size is $166.8M (across 54 rounds with reported amounts).
Portfolio
46
Fund Size
$44B
Top Stage
Series B
Last 12 Mo
2
Team
Alice Lu
Managing Director
Andrew Engebretson
Managing Director
Andrew Hung
Managing Director
Anna McKay
Managing Director
Ben Richardson
Managing Director
Cheryl Leahy
Managing Director
Christine Ma
Managing Director
Christopher A. Devine
Managing Director
Daniel D. Meade
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| AAda Health | Series B | $30M | Sep 2026 |
 Encoded Therapeutics | Series F | $275M | Sep 2026 |
 Mirador | Series B | $250M | Jan 2026 |
 Mirador Tx | Series B | $250M | Jan 2026 |
 Sagimet Biosciences | Series C | $175M | Jan 2026 |
| Encoded Therapeutics | Series F | $275M | Jan 2026 |
| EEncoded | Series F | $275M | Jan 2026 |
 eGenesis | Series D | $191M | Aug 2025 |
 Pentera | Series D | $60M | Mar 2025 |
| MMirador Therapeutics | Unknown | $250M | Jan 2025 |
| Mirador Tx | Series B | $250M | Jan 2025 |
 Ventyx Biosciences | Series A | $27M | Sep 2024 |
 Cardurion Pharmaceuticals | Series B | $260M | Jul 2024 |
| Mirador Tx | Unknown | $400M | Mar 2024 |
 HiBob | Series D | — | Sep 2023 |
 Zentalis | Series C | $85M | Jan 2023 |
 Adia Health | Series B | — | Feb 2022 |
 Metagenomi | Series B | $175M | Jan 2022 |
| AAda Health | Series B | $120M | Jan 2022 |
 Ada | Series B | $30M | Jan 2022 |
| Ventyx Biosciences | Series B | $51M | Sep 2021 |
 BioTheryX | Series E | $92M | May 2021 |
 Affinia | Series B | $110M | May 2021 |
 Lumicks | Series D | $93M | Apr 2021 |
| LLumicks B.V. | Series D | $93M | Apr 2021 |
Top Co-Investors
Last updated: 7 October 2026